InflaRx (IFRX) AI Stock Analysis

• Market Cap: $55.54M
• Dividend Yield: N/A
• Average Volume (3M): 319.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 221,817
• 30 Day Avg. Volume: 319,768
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -16.32
• Enterprise Value/Gross Profit: 0.71
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: $3.60
• Price Target Upside: 318.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: $1.00 ▲(16.28% Upside)

InflaRx's overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and cash flow challenges. Technical analysis indicates weak market momentum, and valuation metrics are unfavorable with a negative P/E ratio. The absence of earnings call data and corporate events does not alter the negative outlook.

Positive Factors

Clinical Development

INF904 is believed to have a potential best-in-class drug profile compared to Amgen's avacopan, with meaningful commercial opportunities in CSU and HS.

Drug Development

Inflarx has completed sub-chronic and chronic toxicology studies with INF904 with no signals identified, which should support long-term dosing in future clinical studies.

Financial Performance

IFRX remains well funded into 2027, ensuring financial stability for ongoing and future projects.

Negative Factors

Clinical Trial Challenges

The Independent Data Monitoring Committee recommended the Phase 3 trial evaluating vilobelimab in PG be stopped due to lack of observed treatment effect.

Market Uncertainty

The uncertainty and high risk/reward aspect associated with clinical trials is a main driver behind the difference between current share price and the target.

Project Timeline

Data from the Phase 2a open-label, dose-ranging 'basket study' testing INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are now expected by the end of September to early November, which is a delay from the prior guidance of Summer 2025.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

How the Company Makes Money

InflaRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may earn income through various channels, including grants, collaborations, and partnerships with larger pharmaceutical companies, which often provide funding in exchange for rights to market or co-develop its products. Additionally, successful clinical trials can lead to milestone payments from partners, while eventual product sales, if approved, will become a significant revenue stream. The company's strategic focus on addressing unmet medical needs in inflammatory diseases also increases its potential for attracting investment and partnerships, driving its earnings.

InflaRx Financial Statement Overview

Summary

InflaRx's financials reflect significant operational and financial challenges. The company is struggling with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	129.75K	165.79K	63.09K	0.00	0.00	0.00
Gross Profit	-2.98M	-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
EBITDA	-45.87M	-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
Net Income	-44.72M	-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet
Total Assets	87.00M	76.02M	120.21M	102.40M	125.14M	88.22M
Cash, Cash Equivalents and Short-Term Investments	65.86M	52.84M	90.27M	81.81M	83.41M	81.13M
Total Debt	702.63K	805.09K	1.12M	1.36M	1.43M	559.04K
Total Liabilities	16.53M	14.60M	17.63M	14.05M	19.86M	10.35M
Stockholders Equity	70.47M	61.42M	102.58M	88.35M	105.28M	77.86M
Cash Flow
Free Cash Flow	-47.75M	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
Operating Cash Flow	-47.70M	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
Investing Cash Flow	43.08M	52.36M	-17.70M	19.36M	-25.95M	21.36M
Financing Cash Flow	27.48M	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.86
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.84, and below the 200-day MA of 1.54, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 52.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	54 Neutral	$90.66M	―	-46.28%	―	-33.00%	54.91%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.76%	-2.28%
IFRX	41 Neutral	$55.54M	―	-62.38%	―	178.84%	-40.60%
CLSD	39 Underperform	$35.24M	―	91.63%	―	-44.63%	26.80%
CABA	39 Underperform	$150.92M	―	-76.34%	―	―	-41.69%
JSPR	35 Underperform	$49.25M	―	-146.87%	―	―	-17.96%